TZ2 (Tirzepatide)

What Is TZ2?

TZ2 (LY3298176) is a synthetic dual receptor agonist research compound that simultaneously activates both the glucagon-like peptide-1 receptor (GLP-1R) and the glucose-dependent insulinotropic polypeptide receptor (GIPR). Developed by Eli Lilly and Company, it is a 39 amino acid peptide incorporating a C20 fatty diacid modification that enables albumin binding and extended half-life in research models, as documented in peer-reviewed pharmacology literature.

Unlike SM1 which targets only the GLP-1 receptor, its GIP receptor co-activation opens additional research dimensions. The GIP receptor is expressed in adipose tissue, bone, the central nervous system and pancreatic beta cells — tissues not directly accessible through GLP-1 receptor research alone.

It represents the critical intermediate between GLP-1 mono-agonist research (SM1) and triple receptor research (RT3), making it an essential compound for comparative incretin pathway studies.

Dual Receptor Mechanism

TZ2 vs SM1 — Key Difference

The defining difference between TZ2 and SM1 is GIP receptor co-activation. While both compounds activate the GLP-1 receptor, only this compound also engages the GIP receptor. This additional receptor pathway provides researchers with access to adipose tissue, bone and additional CNS signalling mechanisms that are not directly studied through GLP-1 receptor agonism alone. It is therefore the compound of choice for research requiring differentiation between GLP-1 and combined GLP-1/GIP pathway effects — researchers studying receptor selectivity often use it alongside SM1 as a paired reference set.

Sizes & Pricing

This TZ2 research guide includes full sizing and reconstitution details below. It's available in three individual vial sizes.

Storage & Reconstitution

Store the lyophilised compound at room temperature away from direct light and moisture. Once reconstituted with bacteriostatic water, store refrigerated at 2–8°C and use within 28 days. Do not freeze reconstituted solution.